Constitutive activation of Akt has been found in many types of human cancer, and is believed to promote proliferation and increased cell survival thereby contributing to cancer progression. In this study, we examined Akt phosphorylation on Ser473 and Thr308 in seven IGF-IIoverexpressing rhabdomyosarcomas (RMS) cells. All the RMS cell lines tested had high levels of Akt phosphorylation on Thr308, whereas three cell lines (Rh5, Rh18, and CTR) had a much lower level of Akt phosphorylation on Ser473. To determine whether the difference in Akt phosphorylation on Ser473, but not on Thr308, observed among cell lines is a cell-specific phenomenon or due to other factors, which possibly downregulate Akt phosphorylation, we examined expression of PTEN protein, which acts as a negative regulator of the PI3K/Akt signaling pathway through its ability to dephosphorylate phosphatidylinositol 3,4,5-triphosphate (PIP 3 ). The levels of PTEN expression inversely correlate with Akt phosphorylation on Ser473, but not on Thr308. Consistent with this finding, transfection of wild-type PTEN into RMS and mouse myoblast C2C12 cells resulted in reduced Akt phosphorylation on Ser473, but not on Thr308. Our data suggest that Ser473 may be a key target residue for PTEN to modulate the effects of IGF-II on activating the PI3K/Akt pathway in RMS cells. A better understanding of the pathway in RMS will likely contribute to insights into the biology of the RMS tumorigenesis and hopefully lead to novel therapeutic options.
Introduction
Akt/PKB is a serine/threonine kinase and exists in three isoforms Akt1/PKBa, Akt2/PKBb, and Akt3/PKBg in mammalian cells. Akt has been well established as an important signaling intermediate in mediating a variety of biological responses such as glucose metabolism, cell proliferation, apoptosis, transcription, and cell migration (Cross et al., 1995; Hemmings, 1997a; Alessi and Cohen, 1998; Medema et al., 2000; Scheid and Woodgett, 2001 ). Furthermore, amplification of genes encoding Akt isoforms have been found in ovarian, breast, prostrate, and pancreatic cancers (Hill and Hemmings, 2002) . Deregulation of Akt has been implicated in the development of human cancer (Brazil and Hemmings, 2001) . Akt is frequently constitutively active in many types of human cancer (Haas-Kogan et al., 1998; Yuan et al., 2000; Nicholson and Anderson, 2002) . Constitutive activation of Akt in human cancer is believed to promote cell survival, proliferation, and growth, thereby contributing to cancer progression. Understanding the regulation of Akt has thus been a major interest in the elucidation of its role and mechanism in regulating physiological and pathophysiological processes.
Akt is activated by a dual regulatory mechanism that requires both translocation to the plasma membrane and phosphorylation at Thr308 in the activation loop of the kinase and Ser473 at the C-terminus (Hemmings, 1997b; Downward, 1998) . Binding of the pleckstrin homology domain (PH) of Akt to phosphatidylinositol 3,4,5, triphosphate (PIP 3 ) on the inner leaflet of the plasma membrane releases the autoinhibitory function of this domain allowing phosphoinositide-dependent kinase 1(PDK1) to phosphorylate Akt on Thr308 (Stokoe et al., 1997; Stephens et al., 1998) . Phosphorylation of Akt is required for its function. Thus, Akt activity is positively regulated by PI3K, which phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP 2 ) to produce PIP 3 (Franke et al., 1997) . Although phosphorylation at Thr308 partially activates Akt (Alessi et al., 1996) , full activation of Akt requires phosphorylation at Ser473 by PDK2 (Toker and Newton, 2000) , a kinase that has been characterized biochemically but the molecular identity of which remains to be determined definitively.
The phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a dual-function lipid and protein phosphatase that was originally identified as a tumor suppressor gene frequently mutated or deleted somatically in a variety human cancers (Li et al., 1997; Steck et al., 1997) . One of the primary targets of PTEN is PIP 3 . PTEN dephosphorylates PIP 3 at the D3 position and thus acts as a negative regulator of PI3K/Akt signaling. Several PTEN-null cell types from both tumors and knockout mice have been demonstrated to have greatly elevated basal levels of Akt activity (HaasKogan et al., 1998; Stambolic et al., 1998; Sun et al., 1999) . Furthermore, recent studies have shown that overexpression of wild-type PTEN suppresses cell growth and proliferation through G1 cell cycle arrest and enhances apoptosis by downregulating PI3K/Akt signaling (Furnari et al., 1997; Davies et al., 1998; Li et al., 1998; Maehama and Dixon, 1998; Ramaswamy et al., 1999) .
In this study, we examined Akt phosphorylation on both Ser473 and Thr308 sites and PTEN expression status in seven rhabdomyosarcomas (RMS) cell lines that overexpress IGF-II. We found that the levels of PTEN expression are related to Akt phosphorylation on Ser473, but not to The308 phosphorylation in all tested RMS cell lines. Furthermore, transfection of wild-type PTEN into RMS cell lines resulted in the reduction of Akt phosphorylation on Ser473, but not on Thr308. Similar results were confirmed in the C2C12 cell line, a mouse myoblast cell line and thus in the same lineage at the skeletal muscle derived rhabdomyosarcomas. These data suggest that Ser473 is a key target residue for PTEN to modulate Akt activation in cells and tumors of skeletal muscle origin.
Results

IGF-II is overexpressed in RMS cells
Elevated levels of IGF-II have been detected in many tumor types and is thought to be an important regulator of cell growth, differentiation, and survival through endocrine and paracrine/autocrine signaling (Reeve et al., 1985; El-badry et al., 1991; Toretsky and Helman, 1996; Wan and Helman, 2002) . We confirmed high IGF-II mRNA expression in seven RMS cells, tumors of skeletal muscle lineage, by Northern blotting analysis. As shown in Figure 1a , IGF-II was highly expressed in all tested RMS cell lines. As a control cell line, mouse myoblast C2C12 cells had a much weaker IGF-II expression.
Expression pattern of Akt isoforms in RMS cells
To elucidate the mechanisms responsible for IGF-IImediated signaling, we have addressed the question of whether overexpression of IGF-II may be linked to the frequently observed activation of PI3K/Akt pathway. Overexpression of Akt2 has been described in ovarian and pancreatic cancers (Cheng et al., 1992 (Cheng et al., , 1996 Bellacosa et al., 1995) , whereas Akt3 is overexpressed in poorly differentiated breast and prostate cancer (Nakatani et al., 1999) . To determine whether there is isoform specificity of Akt expression in RMS, we examined the expression of Akt isoforms in RMS cell lines by RT-PCR. RT-PCR analyses revealed that PKBa/Akt1, PKBb/Akt2, and PKBg/Akt3 are ubiquitously expressed in RMS. By contrast, PKBg-1, a splice variant of PKBg/Akt3 lacking the second phosphorylation site, showed lower expression in all RMS cell lines ( Figure 1b) . Similar results were observed using a lower number of cycles (26 cycles) (data not shown).
Discrepancy between IGF-II overexpression and Akt phosphorylation on ser473, but not on Thr308 in RMS cells
To determine whether Akt is activated in IGF-IIoverexpressing RMS cells, we examined Akt phosphorylation in these RMS cell lines grown under normal growth conditions. As shown in Figure 2a , three of the seven RMS cell lines, Rh4, Rh13, and Rh30, were highly phosphorylated on Ser473. Lower phosphorylation of Akt on Ser473 was detected in Rh5, Rh18, and CTR cell lines, although IGF-II expression is more abundant in Rh5 and Rh18 than in Rh4 and Rh13 cell lines (Figure 1a) . In contrast, all seven cell lines examined displayed high phosphorylation of Akt on Thr308 as well as abundant phosphorylated PDK1 (Figure 2a) . In vitro Akt kinase activity was assessed by immunoprecipitating with a phosphospecific antibody against phosphorylate Ser473 and then using glycogen synthase kinase-3 (GSK-3) as a substrate to measure Akt activity in seven cell lines. High levels of Akt activity correlated with phosphorylation status of Ser473, with highest activity in Rh4, Rh13, and Rh30 cells and lower levels in Rh5, Rh18, and CTR cells (Figure 2b ). These data indicate that there is a discrepancy between IGF-II overexpression and Akt phosphorylation on Ser473 in some RMS cells, but not on Thr308.
To determine whether Akt phosphorylation was dependent on PI3K, we tested the ability of a PI3K inhibitor, wortmannin, to inhibit Akt phosphorylation. Rh13 and Rh18 cells were treated with the PI3K inhibitor wortmannin (250 nm), the p70S6 K inhibitor rapamycin (100 nm), or the MEK inhibitor U0126 (10 mm) for 1 h and then harvested for Western blotting analysis. As shown in Figure 2c , wortmannin completely inhibited Akt phosphorylation on both Ser473 and Thr308 sites, whereas neither rapamycin nor U0126 blocked Akt phosphorylation on either site. These data suggest that Akt phosphorylation in RMS cells is PI3K-dependent. To explore the molecular basis for the discrepancy among these RMS cells in Akt activation linked to IGF-II overexpression, we tested the status of the PTEN tumor suppressor gene, as it has been shown to be a negative regulator of PI3K/Akt activity through its lipid phosphatase function as described in the introduction. Although no PTEN mutations were detected in the RMS cells (data not shown), the levels of PTEN protein expression appear to be inversely correlated with Akt phosphorylation on Ser473. Rh5, Rh18, and CTR cell lines have higher levels of PTEN expression and much lower Akt phosphorylation on Ser473, whereas Rh4, Rh13, Rh30, and RD cell lines have lower levels of PTEN expression and higher levels of Akt phosphorylation on Ser473 (Figure 2d ). These data suggest that the expression of PTEN in RMS cells inversely correlates with Akt phosphorylation on Ser473, but is not correlated with phosphoryltion status of Thr308.
Blockade of IGF-I receptor by aIR3 antibody downregulates Akt phosphorylation on Ser473, but not on Thr308
It is widely believed that IGF-II exerts its effects in the regulation of cell growth, survival, differentiation, and development through the IGF-I receptor, a ligandactivated tyrosine protein kinase with high homology to the insulin receptor (Ullrich et al., 1986; Stewart and Rotwein, 1996) . To determine whether IGF-II ovexpression is correlated with high levels of Akt phosphorylation in RMS cells, we treated Rh13, Rh30 (cells with high Ser473 phosphorylation), and Rh18 (cells with low Ser473 phosporylation) with aIR3, a blocking monoclonal antibody directed against IGF-I receptor, in serum-free medium for 4 h. As shown in Figure 2e , neutralizing antibody against the IGF-I receptor downregulated Akt phosphorylation on Ser473, but not on Thr308, in tested Rh13, Rh30 and Rh18 cell lines. These data suggest that high levels of Akt phosphorylation detected in RMS cells are correlated with IGF-II overexpression and the Ser473 residue seems to be more important in IGF-II-mediated Akt phosphorylation.
Transfection of wild-type PTEN in RMS and C2C12 cells leads to reduction of Akt phosphorylation on Ser473, but not on Thr308
To further assess the relationship of PTEN expression to Akt phosphorylation on Ser473, wild-type PTEN and mutant PTEN (C124S) were transiently transfected into Rh13, Rh30, and RD cells that have lower levels of endogenous PTEN expression (Figure 2d ). The status of PTEN and Akt phosphorylation were examined in the three cell lines after 72 h of transfection. As shown in Figure 3a , transfection of wild-type PTEN resulted in reduced Akt phosphorylation on Ser473, but not on Thr308, in all analysed cell lines. Furthermore, similar data were obtained for Akt enzymatic activity by Figure 2 The levels of PTEN protein expression inversely correlate with Akt phosphorylation on Ser473, but not onThr308. (a) Akt phosphorylation on Ser473 and The308, total Akt, and PDK1 phosphorylation were determined by Western blot analysis in RMS cells. (b) In vitro Akt kinase activity was assessed by immunoprecipitating with phosphospecific antibody against phosphorylated Ser473 and then using GSK-3 as a substrate to measure Akt activity in Rh4, Rh5, Rh13, Rh18, Rh30, RD, and CTR cell lines. (c) Confluent Rh13 and Rh18 cells were treated with wortmanin (250 nm), rapamycin (100 nm), or U126 (10 mm) for 1 h. Cells were lysed in lysis buffer and then subjected to Western blot analysis of Akt phosphorylation on Ser473 and Thr308. (d) Expression of PTEN protein was determined by Western blot analysis in RMS cells. Blots with antibody against actin were used to confirm equal loading of the protein. (e), Confluent Rh13, Rh30, and Rh18 cells were treated with 1 mg/ml MOPC 21 or 0.1B0.2 mg/ ml aIR3 antibodies in serum-free medium for 4 h and then subjected to Western blot analysis of Akt phosphorylation on Ser473 and Akt expression. Similar results were achieved in two separate experiments immunoprecipitating with a phosphospecific antibody against phospho-Akt (Ser473) and then using GSK-3 as a substrate to evaluate Akt activity (Figure 3b) . However, transfection of a mutant PTEN (C124S) failed to alter Akt phosphorylation on Ser473 in the same RMS cell lines (Figure 3c ). In addition to RMS cell lines, transient transfection of wild-type PTEN into C2C12 myoblast cells also led to reduction of Akt phosphorylation on Ser473, but not on Thr308 (Figure 3d ). Taken together, these results suggest that Ser473, but not Thr308, is a key target residue for PTEN to negatively regulate Akt activation.
Discussion
The proto-oncogene Akt/PKB, a target of PI3 kinase activation, has a central role in a signaling pathway of which many components have been linked to metabolism, protein synthesis, cell proliferation, survival, and transcriptional regulation. It is overexpressed as well as activated in numerous human cancers (Tsatsanis and Spandidos, 2000; Hill and Hemmings, 2002) . In this study, we found that mRNA expression of the three major Akt/PKB isoforms are expressed in all RMS cells as indicated by RT-PCR analysis, and lower but detectable expression of the splice-variant, PKBg-1 (Figure 1b ). Since we were unable to selectively detect the protein expression of Akt isoforms with commercially available antibodies, we examined the expression of pan-Akt protein in these RMS cells by Western blot analysis. No significant difference for pan-Akt protein expression was found in these cells (Figure 2a) .
IGF-II is overexpressed in a wide variety of human tumors and has both mitogenic and antiapoptotic activity. Our data show that IGF-II is overexpressed in all RMS cell lines examined (Figure 1a) . All RMS cell lines tested had high levels of Akt phosphorylation on Thr308, whereas three cell lines (Rh5, Rh18, and CTR) had a much lower level of Akt phosphorylation on Ser473 (Figure 2a ). To determine whether high levels of Akt phosphorylation are related to IGF-II overexpression in RMS cells, we treated Rh13, RH18, and Rh30 cells with aIR3 blocking monoclonal antibody against the IGF-I receptor in serum-free medium for 4 h. Blocking the IGF-I receptor resulted in downregulation of Akt phosphorylation on Ser473, but not on Thr308, in Rh13, Rh30, and Rh18 cell lines (Figure 2e) . Thus, the high levels of Akt phosphorylation appear to be correlated with IGF-II expression, although there is a discrepancy between IGF-II overexpression and Akt phosphorylation on Ser473 in some RMS cells, but not on Thr308. These data also suggest that the Ser473 may be a key site for IGF-II to regulate Akt full activation.
To determine whether the difference in Akt phosphorylation on Ser473, but not Thr308, observed among cell lines is a cell-specific phenomenon or due to other factors, which possibly downregulate Akt phosphorylation, we examined expression of PTEN protein by Western analysis. The levels of PTEN expression inversely correlated with Akt phosphorylation on Ser473, but not Thr308. The presence of elevated levels of PTEN expression in Rh5, Rh18, and CTR cell lines might explain lower levels of Akt phosphorylation on Ser473 in these cell lines (Figure 2a and d) . These data suggest that Ser473 may be a target residue of PTEN in the downregulation of Akt activity. To examine this (Figure 3c ). These results demonstrate that Ser473 is a key target residue for PTEN regulation of Akt activation. Our data reveal that Akt phosphorylation is correlated with IGF-II overexpression in RMS cells and the levels of PTEN protein expression modulate IGF-II overexpression-mediated Akt phosphorylation on Ser473. The mechanism by which PTEN regulates Ser473 phosphorylation on Akt is unclear. Phosphorylation at Thr308 by PDK1 partially activates Akt (Alessi et al., 1996) ; full activation of Akt requires phosphorylation at Ser473 by PDK2 (Toker and Newton, 2000), a kinase that has been characterized biochemically but the molecular identity of which remains to be determined definitively. The mechanism mediating phosphorylation at Ser473 residue remains unclear, but is crucial for understanding how Akt is regulated. Mutating the site to an alanine significantly reduces Akt activation (Alessi et al., 1996) . Furthermore, a natural splice variant of Akt3/PKBg (PKBg-1) that lacks this phosphorylation domain is significantly less responsive to growth factor stimulation (Brodbeck et al., 2001) . Our data revealed that all RMS cell lines routinely express Akt1/PKBa, Akt2/PKBb, and Akt3/ PKBg by RT-PCR analysis. However, the splice variant of Akt3/ PKBg (PKBg-1) displays much lower expression in comparison with that of Akt1/PKBa, Akt2/PKB, and Akt3/PKBg in all RMS cells. In most situations, phosphorylation of Akt at Ser473 occurs in tandem with that at Thr308. However, studies have shown that phosphorylation at the two residues can occur independently (Alessi et al., 1996; Kroner et al., 2000) . Ceramide, a pro-apoptotic lipid, has been shown to inhibit Akt by promoting dephosphorylation of Ser473, but not Thr308 (Schubert et al., 2000) . PDK1-null embryonic stem cells maintain the ability to undergo Ser473 phosphorylation (Williams et al., 2000) . The integrin-linked kinase (ILK) has been shown to phosphorylate Akt on Ser473 (Delcommenne et al., 1998; Lynch et al., 1999; Persad et al., 2001a) . Consistent with these findings, our data revealed that PTEN regulates Akt phosphorylation only on Ser473 site. These results suggest that Akt phosphorylation at the two sites may be regulated by different mechanisms. Since ILK is related to Akt phosphorylation on Ser473 and is a candidate Ser473 kinase (Delcommenne et al., 1998; Lynch et al., 1999; Persad et al., 2001a) , we also examined the ILK expression in PTEN-transfected RMS and C2C12 cells. Transfection of PTEN in Rh13, Rh30, RD, and C2C12 cells failed to alter the levels of ILK expression in these cells (data not shown). Thus, the specific effect of PTEN on regulating Ser473 phosphorylation appears to be independent of ILK.
Since PTEN is believed to negatively regulate Akt activation through dephosphorylation of PIP 3 at the D3 position, which should effect phosphorylation of both Akt sites, this raises the question of whether PTEN regulates Ser473 phosphorylation on Akt through an unknown mechanism that may be PIP 3 -independent. The cellular distribution of PIP 3 within the plasma membrane is often not evenly distributed, depending upon the cell type and environment of the cell, and the effects of this on downstream processes may be significant (Leslie and Downes, 2002) . Although PTEN clearly acts as a lipid phosphatase in many cell types, it has been shown to dephosphorylate protein substrates as well and may have roles other than antagonizing PI3K. Focal adhesion kinase (FAK) has been proposed as a protein substrate of PTEN (Tamura et al., 1998) . The mitogen-activated kinase (MAPK) pathway is another critical pathway for proliferation and differentiation. PTEN also downregulates this pathway (Takahashi-Tezuka et al., 1998; Weng et al., 2001) . A recent study revealed another potentially important feature of PTEN function in which re-expression of PTEN in PC3 and LNCaP cells resulted in degradation of b-catenin (Persad et al., 2001b) . PTEN has also been demonstrated in the nuclear compartment of cells, although it lacks a nuclear-localization sequence (Tamura et al., 1998; Gimm et al., 2000; Lachyankar et al., 2000) . The mechanism by which PTEN can transport into the nuclear compartment remains to be elucidated. It is unclear whether nuclear PTEN could act on lipids in the nuclear membrane and could regulate the activity of various transcription factors. These findings suggest that the roles of PTEN may be broader than dephosphorylation of PIP 3 .
The obvious discrepancy between our data and published reports in glioma cells and breast cancer cells, where PTEN dephosphorylates both Ser473 and Thr308 (Davies et al., 1998; Ghosh et al., 1999; Wick et al., 1999) , could be the result of different cell types. Wortmannin, a PI3K inhibitor, inhibits Akt phosphorylation on the both sites (Figure 2c ), but PTEN inhibits Akt phosphorylation on Ser473. These results imply that PI3K/PIP 3 -dependent and PI3K/PIP 3 -independent mechanisms may be involved in the regulation of Akt phosphorylation on Thr308 depending on different cell types. Although the PIP 3 -independent mechanism of regulating Akt phosphorylation remains unclear, the continuing investigation into the many aspects of PTEN function will lead to a better understanding of how PTEN regulates PI3K/Akt pathway to affect tumor development and progression. Since constitutive Akt signaling is believed to promote cell proliferation and survival and thereby contribute to cancer progression, the inhibition of Akt signaling, either directly or by interfering with its upstream regulators, is likely to represent an effective and widely applicable anticancer strategy.
Material and methods
Cell culture
Rh4, Rh5, Rh13, Rh18, and Rh30 alveolar RMS cells were kindly provided by Dr P Houghton (St Jude's Children's Research Hospital). RD and CTR embryonal RMS cells were obtained from the American Type Culture Collection and Dr M Tsokos (National Cancer Institute). These cells were maintained in RPMI 1640 containing 10% fetal bovine serum, l-glutamine (2 mm), penicillin (100 U/ml), and streptomycin (100 U/ml) (BioSource International Inc, Camarillo, CA, USA) at 371C, 5% CO 2 in a humidified incubator. The mouse C2C12 myoblast cells were obtained from the American Type Culture Collection and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mm glutamine, 100 U/ml penicillin, and streptomycin at 371C, 5% CO 2 in a humidified incubator.
Northern blot analysis
Total RNA was isolated from RMS cells by using Rneasy Midi Kit (Qiagaen, Valencia, CA, USA). Total RNA (20 mg) was separated on a 1% formaldehyde-agarose gel, transferred to a Hybond-N þ membrane (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and crosslinked to the membrane in an UV cress-linker (Stratagene, La Jolla, CA, USA). The fulllength human IGF-II cDNA probe was labeled using rediprimet II kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Hybridization was carried out at 651C in Rapidhyb buffer (Amersham Pharmacia Biotech, Piscataway, NJ, USA) for 1 h and washed three times with 2 Â SSC/0.1% sodium dodecyl sulfate (SDS) at room temperature, and twice with 0.1 Â SSC/0.1% SDS at 651C before being subjected to autoradiography.
RT-PCR analysis of Akt/PKB isoforms in RMS cells
Total RNA was extracted from seven RMS cell lines with an Rneasy Midi Kit (Qiagaen, Valencia, CA, USA). RNA (5 mg) from each cell line was reverse-transcribed into cDNA using a first-strand cDNA synthesis kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. Akt/PKB isoforms were amplified using 35 cycles of PCR (951C for 1 min, 551C for 1 min, and 721C for 1 min) with a final 7-min incubation at 721C using Ready-To-Go PCR Beads (Amershan Pharmacia Biotech, Piscataway, NJ, USA). Primer sequences used are: Akt1/PKBa, 5 0 -GCTGGAC-GATAGCTTGGA-3 
Cell lysis
Cells cultured under desired conditions were lysed in lysis buffer (20 mm Tris-HCI, pH 7.5; 150 mm sodium chloride; 1 mm EDTA; 1mM EGTA; 1% Triton; 2.5 mm sodium pryophosphate; 1 mm b-glycerolphosphate; 1 mm sodium orthovandate; 0.5 mm phenylmethylsulfonyl fluoride; 1 mg/ml leupeptin). The lysates were centrifuged at 13000 g, supernatants were removed and stored at À801C until use. 
Akt/PKB kinase assay
Confluent seven RMS cells were lysed in lysis buffer described as above. Protein concentrations in cell extracts were determined by Bio-Rad protein assay. Akt kinase activity was assessed using Akt kinase assay kit (Cell Signaling Technology Inc., Beverly, MA, USA) according to the manufacturer's instructions. Protein (300 mg) from lysate samples were immunoprecipitated with phospho-Akt (Ser473) antibody crosslinked to agarosehydrazide beads overnight at 41C. The immunoprecipitates were washed twice in lysis buffer and twice in kinase assay buffer (25 mm Tris, pH7.5, 5 mm b-glycerolphosphate, 10 mm MgCl 2 , 0.1 mm sodium orthovanadate, 2 mm dithiothreitol). The samples were resuspended in 40 ml kinase assay buffer containing 200 mm ATP and 1 mg GSK-3 fusion protein and allowed to proceed at 301C for 30 min. Reaction products were resolved by 4-20% SDS-PAGE followed by Western blotting with a phospho-GSK-3a/b antibody.
aIR3 treatment in Rh13, Rh30, and Rh18 cells Rh13, Rh30, and Rh18 cells were grown in six-well culture dishes in RPMI 1640 containing 10% fetal bovine serum, lglutamine (2 mm), penicillin (100 U/ml), and streptomycin (100 U/ml) at 371C, 5% CO 2 in a humidified incubator. Confluent cells were treated with 1 mg/ml isotype-matched control antibody (MOPC 21) (Sigma Chemical Co., St Louis, MO, USA) as a control and 0.1B0.2 mg/ml aIR3 (Oncogene Science, Cambridge, MA, USA), a monoclonal antibody against IGF-1 receptor, in serum-free medium for 4 h.
Transient transfection
Rh13, Rh30, RD RMS, and C2C12 cells were transiently transfected with an expression vector (pCMV) containing human wild-type PTEN or mutant PTEN (C124S), kindly provided by Dr J Dixon (Maehama and Dixon, 1998) , or a empty vector alone using electroperation in a Bio-Rad gene Pulsar (0.22 kV/cm; capacitance, 960 mF). Cells were harvested 72 h after electroperation and lysed in lysis buffer described as above. The expression of PTEN in transfected cells was confirmed by Western blotting using anti-PTEN antibody.
